Cohance Lifesciences has approved a fund infusion into its subsidiary, NJ Bio Inc. USA, through an investment in Compulsorily Convertible Preferred Stock. The investment will be up to USD 10 million. The funds will be used to support the subsidiary’s growth initiatives, including capital expenditure (capex). The decision was made by the Board of Directors on December 2, 2025.
Fund Infusion Approval
The Board of Directors of Cohance Lifesciences has given the go-ahead for a fund infusion into NJ Bio Inc. USA, a subsidiary of the company. The decision was made during a board meeting held on December 2, 2025.
Details of the Investment
The fund infusion will be executed through an investment in Compulsorily Convertible Preferred Stock of NJ Bio Inc. The total investment amount is capped at USD 10 million. The funds are earmarked to bolster the subsidiary’s growth strategy. A substantial portion of the investment will be directed towards capital expenditure (capex) and related initiatives.
Source: BSE